Currently, Kevin J. Scanlon is the chairman of Pasadena Angels investment and is using his academic and business experience to mentor creative scientific ideas with good business practices to generate novel medical products. Entrepreneurs are supported with a strong management team and venture capital (Angel Funding) to make the successful transition from concept into a productive enterprise.
Professor Scanlon was responsible for the development and teaching of the Pharmaceutical Development graduate courses at the Keck Graduate Institute in Claremont, Ca. (2000-2004). He was the faculty coordinator for the summer internship program and the team masters research program sponsored by the Bio-Pharmaceutical Industry. He was also the Principal Investigator of a $600,000 federally funded grant entitled “Partnerships for Innovation” to support the development of entrepreneur businesses with the Bioscience Community. From 2000, Dr. Scanlon has been on the Scientific Advisory Board for the first European Biotechnology Institute in Dublin, Ireland. (Advisory Boards)
Dr. Scanlon has previously served in the Senior Management Team for Berlex Biosciences, a division of Schering AG in Berlin, Germany from 1996-2000. He was responsible for developing their international cancer program, which involved developing medical products for diagnostics, small molecules and gene therapy projects. Dr. Scanlon has extensive management skills for creating, planning, organizing and implementing complex scientific programs with internal and external collaborations by identifying and validating clinical candidates for development with the FDA and marketing strategies. (Industry)
Dr. Scanlon is a molecular biologist and gene therapist. He was the President of the International Society of Cancer Gene Therapy (2001-2003) in London, England. His previous research involved training of thirty international Post-Doctoral Fellows in molecular biology and gene therapy. Their research involved developing viral vectors (retro and adeno viruses) for delivery of anti-cancer ribozymes for human tumors. These studies were presented at an international conference on "Medicine in the 21st Century" in Valencia, Spain (1998). Prior work had established the utility of anti-oncogene ribozymes to reverse the malignant phenotype of human melanoma and human bladder carcinoma in vivo. This program was presented at the 400th Anniversary of Uppsala University, Sweden (1995) where ten invited international speakers discussed their newest medical advances. The initial research of this program involved elucidating the biochemical mechanism for synergistic combination cancer chemotherapy in patients (cisplatin/5-flurouracil), which lead to the optimization of DNA damaging agents with nucleoside analogues (AZT and Gemcitabine). This work was awarded the Paul Martini International Medical Research Prize (1988) in Bonn, Germany.
Dr. Scanlon received his Ph.D. in Biochemistry from the University of London, London, England and his Post-Doctoral training in Molecular Pharmacology at Yale School of Medicine New Haven, CT. He was both a Leukemia Society of America Fellow and Leukemia Scholar. Currently, he is co-editor of the journal Cancer Gene Therapy and the Internet Book of Gene Therapy for Cancer Therapeutics. He is on several Editorial Boards, Funding Agencies and Scientific Advisory Boards. He has published over 120 papers in the fields of Cancer and Gene Therapy. He has been a reviewer and committee chairman for the National Institute of Health over the past 15 years, including reviewing grants on the SBIR study section, R01 investigator grants and Cancer Center Program Projects. (Science)